Clinical Trials Browser

Phase 1 × OTHER × MK 2206 × Clear all

NCT01235897 2014-04-17

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

Phase 1 Completed

17 enrolled 7 charts

Neoplasms

NCT01147211 2013-05-03

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung